```html

Homatropine Toxicity – A Complete Patient Guide

Overview

Homatropine (also called homatropine hydrochloride) is a synthetic anticholinergic drug used primarily in ophthalmology to dilate the pupil (mydriasis) and paralyze the ciliary muscle (cycloplegia) for eye examinations or surgery. Although generally safe when used as prescribed, accidental or intentional overdose can cause systemic anticholinergic toxicity, known as homatropine toxicity.

Because homatropine is readily available in eye‑drop bottles, children, the elderly, or individuals with mental‑health disorders are most at risk for accidental ingestion or misuse. Exact prevalence data are limited; however, anticholinergic toxicity accounts for an estimated 2–3% of emergency department (ED) visits for accidental poisonings in the United States each year, and homatropine is among the top five ophthalmic agents involved.

Symptoms

Symptoms reflect widespread blockade of the neurotransmitter acetylcholine at muscarinic receptors. They can appear within minutes of ingestion or ocular administration and range from mild to life‑threatening. The classic “anticholinergic toxidrome” includes:

Central nervous system

• Altered mental status – confusion, agitation, hallucinations, or delirium.
• Hallucinations – visual, auditory, or tactile; patients may describe “seeing insects” (formication).
• Seizures – rare but reported in high‑dose exposures.
• Coma – in severe cases.

Autonomic (Dry) Signs

• Dry mouth (xerostomia) and thick, cotton‑mouth feeling.
• Reduced sweating (anhidrosis) – leading to hyperthermia.
• Flushed, hot skin – “red as a beet.”
• Dilated pupils (mydriasis) – non‑reactive to light.
• Blurred vision – due to loss of accommodation.
• Urinary retention – difficulty initiating urination.

Cardiovascular

• Tachycardia – rapid heart rate, often >100 bpm.
• Palpitations or arrhythmias (rare).

Gastrointestinal

• Constipation – reduced bowel motility.
• Nausea or vomiting – paradoxically may occur.

Other

• Decreased bowel sounds and paralytic ileus in massive overdose.
• Skin hyperthermia – core temperature >38 °C (100.4 °F).

Causes and Risk Factors

How Toxicity Occurs

• Oral ingestion – swallowing eye drops (common in children).
• Intravenous or intramuscular injection – intentional self‑harm.
• Excessive topical use – applying more drops than prescribed, especially in infants.
• Drug interactions – concurrent use of other anticholinergics (e.g., antihistamines, tricyclic antidepressants) can potentiate toxicity.

Populations at Higher Risk

• Children under 6 years – attracted to the sweet taste of many eye‑drop formulations.
• Elderly patients – polypharmacy increases cumulative anticholinergic load.
• Individuals with psychiatric illness – may attempt deliberate overdose.
• Patients with renal or hepatic impairment – slower clearance of the drug.

Diagnosis

Diagnosis is primarily clinical, based on a compatible history and the characteristic anticholinergic toxidrome.

History & Physical Examination

• Ask about recent eye‑drop use, accidental ingestion, or intentional overdose.
• Identify co‑administered anticholinergic medications.
• Document vital signs (temperature, heart rate, blood pressure, respiratory rate).
• Examine pupils (dilated, non‑reactive), skin (dry, flushed), and mental status.

Laboratory & Toxicology Tests

• Serum anticholinergic activity (SAA) – research tool, not routinely available.
• Basic metabolic panel – to assess electrolyte disturbances, renal function.
• Urinalysis – may show anticholinergic metabolites.
• Point‑of‑care toxicology screen – can detect common anticholinergics but not homatropine specifically.

Imaging (if indicated)

• Chest X‑ray for aspiration pneumonia if vomiting is severe.
• CT head if seizures or focal neurologic deficits develop.

Treatment Options

Management focuses on supportive care, decontamination, and reversal of anticholinergic effects.

Immediate First‑Aid (Pre‑hospital)

• Call emergency services (911 in the U.S.).
• Do not induce vomiting unless instructed by a poison‑control center.
• If within 1 hour of ingestion and the patient is alert, activated charcoal (1 g/kg) may be administered by EMS.

Hospital‑Based Care

1. Stabilize airway, breathing, circulation (ABCs). Provide supplemental O₂ if SpO₂ < 94%.
2. Intravenous fluids to maintain perfusion and promote renal clearance.
3. Temperature control – external cooling for hyperthermia.
4. Pharmacologic reversal:
   • Physostigmine (2 mg IV over 5 min; repeat 1 mg every 15–30 min up to 7 mg total) is the antidote of choice for severe central anticholinergic toxicity, provided there are no contraindications (e.g., cardiac conduction disease, asthma). Monitor ECG for bradyarrhythmias.
   • For seizures, use benzodiazepines (e.g., lorazepam 0.1 mg/kg).
   • Control agitation with haloperidol or diazepam** if physostigmine is unavailable.
5. Monitoring:
   • Continuous cardiac telemetry for at least 24 h.
   • Serial neurologic examinations.
   • Urine output >0.5 mL/kg/h.
6. Psychiatric evaluation if overdose was intentional.

Discharge Planning

• Observe for at least 6 hours after symptom resolution.
• Provide written instructions on medication safety.
• Arrange follow‑up with primary care or ophthalmology.

Living with Homatropine Toxicity

For patients who have experienced toxicity (especially from chronic misuse), ongoing management includes:

• Medication review – work with pharmacists to eliminate unnecessary anticholinergic drugs.
• Education – keep eye‑drop bottles out of reach of children; use child‑proof caps.
• Hydration – adequate fluid intake helps renal clearance.
• Monitoring for residual effects – some patients report lingering memory issues; neuro‑cognitive testing may be helpful.
• Psychological support – counseling for patients with intentional overdose.

Prevention

1. Safe storage – store homatropine eye drops in locked cabinets or high shelves.
2. Labeling – keep original packaging; attach “Do Not Ingest” stickers.
3. Educate caregivers – teach parents, nurses, and home‑health aides about the risks.
4. Limit prescriptions – prescribe the smallest effective volume and duration.
5. Medication reconciliation – at every healthcare encounter, review all anticholinergic agents.
6. Poison‑control hotline – keep 1‑800‑222‑1222 handy for immediate advice.

Complications

If untreated or delayed, homatropine toxicity can lead to serious sequelae:

• Hyperthermia → rhabdomyolysis, renal failure.
• Severe arrhythmias (e.g., ventricular tachycardia) due to tachycardia.
• Aspiration pneumonia from decreased gag reflex.
• Prolonged cognitive impairment – memory loss, decreased executive function.
• Death – rare but reported in massive ingestions, especially in the elderly.

When to Seek Emergency Care

References

1. Mayo Clinic. Anticholinergic toxicity. 2023. https://www.mayoclinic.org
2. Centers for Disease Control and Prevention. Poisoning Surveillance System. 2022. https://www.cdc.gov
3. National Institutes of Health. Physostigmine for Anticholinergic Poisoning. 2021. PubMed
4. Cleveland Clinic. Homatropine Eye Drops: Uses and Risks. 2024. https://my.clevelandclinic.org
5. World Health Organization. Guidelines for the Management of Poisonings. 2020. https://www.who.int

```